Intradermal injection Market Research Report and Outlook by 2028

The intradermal injection sector is anticipated to grow significantly, with projections indicating it will reach approximately US$ 7,415.70 million by 2028, up from US$ 3,513.26 million in 2021. This growth represents a compound annual growth rate (CAGR) of 11.3% from 2021 to 2028.

This report outlines the prevailing trends and key factors propelling the growth of the intradermal injection market. The expansion of this market is primarily driven by the increasing use of intradermal vaccinations, a rise in the incidence of various diseases, and a growing acceptance of aesthetic procedures. Furthermore, strategic advancements by manufacturers are expected to play a crucial role in shaping market trends throughout the forecast period. However, challenges such as risks, complications, and limitations in dosing associated with intradermal injections may hinder market growth.

Both developing and developed nations are prioritizing their healthcare sectors, leading to a substantial rise in healthcare spending aimed at enhancing medical infrastructure and services. To meet the escalating global demand, numerous pharmaceutical companies are focusing on the development of effective drugs and devices, with intradermal injections emerging as a promising option for treatment, diagnosis, vaccination, and cosmetic applications. The growing acceptance of intradermal vaccination is a significant factor driving the global intradermal injection market, as this method offers several advantages over traditional vaccination techniques. Intradermal vaccination can reduce the required antigen dose, enhance the immune response elicited by the vaccine, and alleviate anxiety related to vaccination. By utilizing intradermal injections, a larger segment of the population can be vaccinated with a lower volume of vaccine production, making it particularly beneficial for vulnerable groups with comorbidities, as the likelihood of adverse reactions is lower compared to conventional vaccination methods. Recently, various intradermal vaccines for COVID-19, hepatitis A and B, influenza, polio, measles, rabies, tetanus, yellow fever, and diphtheria-tetanus-pertussis have demonstrated improved response rates, prompting leading pharmaceutical and biotechnology firms to invest in the development of intradermal injections for both new and existing vaccines. Notably, in 2020, Sanofi received FDA approval for its intradermal influenza vaccine, Fluzone, which is rapidly gaining traction in the influenza vaccine market, potentially replacing traditional treatments for these diseases.

Moreover, over one-third of the global population is at risk of developing tuberculosis, leading to a notable increase in tuberculosis skin test procedures in recent years. Intradermal tuberculin syringes are essential for diagnosing tuberculosis, and several prominent manufacturers of drug delivery devices are currently innovating these syringes. Additionally, the prevalence of allergies has surged in the past decade, largely due to heightened awareness of various allergy-related conditions. Intradermal injections serve as an effective tool for conducting sensitivity tests for numerous allergens.

The demand for local aesthetic procedures is also on the rise, with nonsurgical cosmetic procedures increasing by 51.4% from 2011 to 2017, according to ISAPS estimates. Furthermore, many new intradermal vaccines are expected to gain approval, as intradermal vaccination is known to elicit a better immune response while minimizing the required dosage and adverse effects. Studies have also indicated that intradermal injections can enhance the uptake of various cancer and immunological therapies, and they may be utilized for gene therapy delivery. The ongoing rise in COVID-19 cases further underscores the potential of this market segment, as numerous intradermal preparations are currently under investigation and poised for approval in the near future. As the global population continues to grow, the incidence of diseases is expected to rise, thereby increasing the demand for intradermal injections. Innovative intradermal devices, such as PharmaJet's Tropis ID, have shown promising results in delivering a variety of drugs targeting a wide range of diseases, thereby broadening the therapeutic applications of intradermal products.

Despite the advantages of intradermal injections, there are also several drawbacks associated with these drug delivery systems, including injection site reactions and dosing limitations, which pose significant challenges for the intradermal injection market. Common side effects include skin discoloration, swelling, redness, itching, and irritation at the injection site. Researchers are actively working to identify optimal injection sites based on the drug's nature and intended action to mitigate these issues.

In recent years, there has been continuous innovation in intradermal injection procedures and devices, with several new technologies being integrated into this sector to advance its development. The rates of vaccination and diagnosis for various conditions have surged over the last decade, leading to increased acceptance of intradermal injections.

Companies in the intradermal injection market are employing various organic and inorganic strategies for growth. Organic strategies primarily involve product launches and approvals, while inorganic growth strategies include acquisitions, collaborations, and partnerships. These strategies enable market players to expand their operations and enhance their geographic reach, contributing to the overall growth of the intradermal injection market. Additionally, acquisition and partnership strategies help companies strengthen their customer base and broaden their product offerings. Notable developments in the intradermal injection market include:

- In November 2021, NanoPass Technologies and Aesthetic Management Partners entered into a partnership to commercialize NanoPass's MicronJet 600 intradermal delivery device in the United States.

- In August 2021, PharmaJet and Zydus Cadila received Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world's first Plasmid DNA Vaccine for COVID-19, which is administered exclusively using the PharmaJet Tropis Needle-free Injection System.

The World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the National Health and Wellness are among the primary and secondary sources referenced in the preparation of this report on the intradermal injection market.